Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
Keishi YoshidaAtsushi FujitaHidehiko NarazakiTakeshi AsanoYasuhiko ItohPublished in: Cancer chemotherapy and pharmacology (2021)
This study reports that nelarabine with vorinostat can promote cytotoxicity in nelarabine-resistant leukemia cells through epigenetic mechanisms.